Morningstar

Kyverna Therapeutics Inc KYTX

Morningstar Rating

Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024

PR Newswire Sep 18, 2024 12:00pm
Kyverna Therapeutics Announces Leadership Update

PR Newswire Sep 16, 2024 12:00pm
Kyverna Therapeutics to Participate in Upcoming September Investor Conferences

PR Newswire Aug 21, 2024 8:05pm
Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

PR Newswire Aug 12, 2024 8:08pm
Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis

PR Newswire Aug 12, 2024 8:05pm
Kyverna Shares Rise After FDA Gives Special Designation to Stiff-Person Treatment

Global News Select Jul 15, 2024 10:57pm
Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome

PR Newswire Jul 15, 2024 8:05pm
Kyverna Therapeutics Shares Rise 13% After FDA Clearance for KYV-101

Global News Select Jun 20, 2024 3:16pm
Kyverna Therapeutics Gets FDA IND Clearance for KYV-101

Global News Select Jun 20, 2024 1:45pm
Wall Street hungry for IPO of Mexican supermarket chain BBB Foods as stock rises 9%

MarketWatch Feb 9, 2024 9:29pm

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2024 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.